A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: Paliperidone ER (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Official(s) and/or principal investigator(s): Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary
The purpose of this study is to evaluate the effects of a CYP2D6 inhibitor, paroxetine, on
the pharmacokinetics of a single dose of orally administered paliperidone ER and to evaluate
the safety and tolerability of both treatments in healthy men
Clinical Details
Official title: A Randomized, Open-label, Single-center, Crossover Study of the Potential Effects of Paroxetine on the Pharmacokinetics of a Single Dose of Paliperidone Extended-release in Healthy Men
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To evaluate the effects of a CYP2D6 inhibitor, paroxetine, on the pharmacokinetics of a single dose of orally administered paliperidone ER
Secondary outcome: To evaluate the safety and tolerability of the 3 mg tablet of paliperidone ER administered with and without paroxetine to healthy men
Detailed description:
This is a randomized, open-label, single-center, single-dose, 2 treatment, 2 way crossover
study. It consists of 3 phases: a screening phase beginning within 21 days before the first
study drug administration; an open label treatment phase consisting of 2 treatment periods
(Period 1 and Period 2), during which patients will receive 2 single doses of 3 mg
paliperidone ER; and end of study evaluations upon completion of all the study procedures in
Period 2 or at early withdrawal. All volunteers will receive each of the following 2
treatments in random order: Treatment A: 1 tablet of 3 mg paliperidone ER in the fasted
state; Treatment B: one 20 mg paroxetine tablet once a day from Day 1 to Day 13 and 1 tablet
of 3 mg paliperidone ER on Day 10 in the fasted state. Successive paliperidone ER
administrations will be separated by a washout period of at least 14 days and no more than
28 days. Paroxetine is a potent and selective CYP2D6 inhibitor. Inhibitors of CYP2D6 such as
paroxetine have been reported to increase the plasma concentrations of antipsychotics such
as perphenazine, clozapine, and risperidone. Because paliperidone ER and paroxetine could
potentially be used in combination in schizophrenic patients, the potential for a drug-drug
interaction between paroxetine and paliperidone ER needs to be explored. The safety and
tolerability of the 3 mg tablet of paliperidone ER administered with and without paroxetine
to healthy men will be monitored.
Two single oral doses of paliperidone ER 3-mg; 20-mg paroxetine orally once a day for 13
days
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Body mass index (weight [kg]/height [m2]) of 18 to 30 kg/m2, inclusive
- Extensive metabolizer of CYP2D6. Volunteers whose CYP2D6 genotype is unknown should
have been phenotyped before the start of the study using dextromethorphan as a probe
(i. e., have a dextromethorphan metabolic ratio <0. 02, as determined according to the
standard procedures of the study center)
- Have a supine (after 5 minutes rest) blood pressure between 100 and 140 mmHg
systolic, inclusive, and 50 and 90 mmHg diastolic, inclusive
- Smokes no more than 10 cigarettes, or 2 cigars, or 2 pipes per day and has been
following this pattern for at least 3 months before screening
- Healthy on the basis of a prestudy physical examination, medical history, 12-lead
ECG, and the laboratory results of serum chemistry, hematology, and urinalysis
performed within 21 days before the first dose. If the results of the serum
chemistry, hematology, or urinalysis testing are not within the laboratory's
reference ranges, the volunteer can be included only if the investigator judges that
the deviations are not clinically significant. For renal function tests, the values
must be within the normal laboratory reference ranges
Exclusion Criteria:
- Poor or intermediate metabolizers of CYP2D6, as determined by genotyping or
phenotyping using dextromethorphan
- Known drug allergy to risperidone, paliperidone, paroxetine, or any of their
excipients
- Known history of drug-induced dystonia
- Recent history of alcohol or substance abuse
- Relevant history or presence of any cardiovascular (including myocardial infarct or
cardiac arrhythmia), respiratory, neurologic (including seizures), psychiatric,
renal, hepatic, gastrointestinal (including surgeries, severe gastrointestinal
narrowing, and malabsorption problems), endocrine, hematologic, or immunologic
disease
- History of any cancer, with the exception of basal cell carcinoma
- At screening, has signs of autonomic dysfunction as indicated by a sustained decrease
of >20 mmHg in systolic blood pressure or a decrease of >10 mmHg in diastolic blood
pressure after standing for at least 2 minutes that is not associated with an
increase of >15 beats per minute (bpm) in heart rate
- Bradycardia (heart rate <50 bpm) as determined by screening 12-lead ECG
- A positive test result (or history of) for any of the serology tests (hepatitis B and
C, and human immunodeficiency virus) at screening
Locations and Contacts
Additional Information
A study of the effects of paroxetine on the pharmacokinetics of paliperidone ER
Starting date: March 2006
Last updated: May 18, 2011
|